Aurobindo Pharma shows strong momentum as markets reward operational progress.

Aurobindo Pharma shows strong momentum as markets reward operational progress. The drugmaker's stock gained 9% in a month, outperforming the pharma index, driven by expanding European sales now representing over 31% of revenue and new US generic launches. Key catalysts include the Pen G and 6-APA backward-integration project reaching breakeven with production ramping to 9,000-10,000 tonnes annually, plus the Lannett acquisition integration delivering synergies. The Dayton sterile facility entered commercial phase while China's oral solid dosage unit approaches breakeven. Government price resets on antibiotics from FY27 should further improve profitability. Analysts project 21% annual earnings growth through FY28, with target prices suggesting 13% upside potential from current levels.